News Category
Italian pharmaceutical company DuLac Farmaceutici is expanding its U.S. presence through a new e-commerce partnership with OneLavi and participation i...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate program into preclinical development, marking a key milestone and expanding it...
Onco-Innovations has signed a letter of intent to potentially license a novel oral small-molecule LAG-3 inhibitor, which could enhance its immuno-onco...
Earth Science Tech's acquisition of Zoolzy LLC aims to enhance its compounding pharmacy operations by securing competitive API pricing and expanding i...
SCHOTT Pharma's updated climate targets, validated by the SBTi, shift focus to absolute Scope 3 emissions reductions, marking a significant step in al...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is progressing with enrollment completed and topline data expected in Q4 2026, ...
VERAXA Biotech announced the advancement of its VXA-222 bispecific antibody-drug conjugate program beyond the discovery phase, leveraging OmniAb's ant...
Tonix Pharmaceuticals announced FDA feedback supporting an adaptive Phase 2 field study for its Lyme disease prevention candidate TNX-4800, marking a ...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed key discovery work, moving t...
VERAXA Biotech AG has appointed Christoph Erkel, Ph.D., as chief scientific officer, leveraging his two decades of antibody therapeutics experience to...
NanoViricides announced a $3.8 million registered direct offering with a single institutional investor, providing capital to advance its broad-spectru...
VERAXA Biotech AG appointed Christoph Erkel as Chief Scientific Officer to lead advancement of its proprietary BiTAC(R) platform for cancer therapies ...
VERAXA Biotech AG announced positive Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE program, reducing development un...
VERAXA Biotech announced Scientific Advice from Germany's Paul-Ehrlich-Institute, validating its dual-targeting BiTAC-TCE platform and supporting its ...
Siegfried appoints Eduardo Montanha as Chief Operating Officer to lead its global manufacturing network, supporting the company's strategy to offer in...
NextPlat Corp acquires a rural Florida pharmacy for $1.5 million to expand PharmcoRx into an underserved market, leveraging same-day delivery and 340B...
Onco-Innovations Limited announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key...
VERAXA Biotech has initiated cell line development for its lead BiTAC(R) T-cell engager program by partnering with ATUM, marking a key step toward IND...
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by chroni...
VERAXA Biotech provided a corporate and pipeline update highlighting advancement of its proprietary BiTAC platform and growing interest from potential...
VERAXA Biotech announced the start of cell line development for its lead BiTAC T-cell engager program, aiming to reduce off-tumor toxicity in cancer t...
The article highlights that VERAXA Biotech AG's technology platform in antibody-drug conjugates and T-cell engagers places it favorably for potential ...
Ace Therapeutics announces full-spectrum preclinical analgesic drug development services with validated in vivo pain models and integrated research ca...
Medios AG is closing its Aschaffenburg facility and consolidating production to improve efficiency and profitability, affecting 32 employees.
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics (TSX: GUD) has fully repaid the $60 million drawn from its revolving credit facility in June 2025 to finance the acquisition of Pa...
Voyageur Pharmaceuticals is evaluating sites in Oklahoma and Texas for a vertically integrated contrast media facility that could reduce costs and sec...
Earth Science Tech Inc. (ETST) has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emph...
Voyageur Pharmaceuticals has submitted a multi-year area-based exploration permit application for its Frances Creek barite project, including a 2,000-...
Voyageur Pharmaceuticals has closed a non-brokered private placement raising $5,005,278.32 to fund FDA licensing for its barium contrast products, reg...
Kairos Pharma announced plans to acquire worldwide rights to Phase 1-ready CL-741, an oral c-MET kinase inhibitor, and provided updates on its lead ca...
Quantum BioPharma's lead drug candidate Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its commercial produ...
Quantum BioPharma is progressing a clinical-stage multiple sclerosis program with a novel approach targeting demyelination, alongside a diversified po...
Redwood AI Corp. announced DTC eligibility for its common shares to simplify U.S. trading and enhance liquidity, and engaged InvestorBrandNetwork for ...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is expanding into the U.S. market, highlighted by ...
Sino Biological's new XPressMAX™ kit enables ultra-fast, high-throughput protein synthesis in 3 hours, integrating with AI-driven screening to speed a...
NanoViricides updates progress on broad-spectrum antiviral NV-387, with regulatory approval for Phase II MPox trial in DRC and FDA orphan drug designa...
NanoViricides has agreed to sell shares and warrants to an institutional investor for gross proceeds of $2 million, with funds likely supporting its l...
Lantern Pharma closed a $4.4 million registered direct offering, with potential for an additional $4.85 million from warrants, to fund its AI-powered ...
Tonix Pharmaceuticals announced its participation in two May investor conferences, highlighting its commercial-stage CNS and immunology pipeline, incl...
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, providing a real-time molecular intelligence engine...
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor, in multiple clinical trials for solid tumors with high unmet medica...
Soligenix Inc. uses its synthetic hypericin platform to target cutaneous T-cell lymphoma and psoriasis, demonstrating how platform-based drug developm...
PolyPeptide Group AG shareholders approved all board proposals, including re-election of directors and auditors, at the company's fifth annual general...
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing a year of leadership changes, clinical advancement of its lead compoun...
LIXTE Biotechnology’s LB-100, the only clinical-stage PP2A inhibitor, shows promise in enhancing cancer therapy by sensitizing tumors to immunotherapy...
Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board of Directors, bringing extensive pharmaceutical industry experience and expertis...
